¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"multiple endocrine neoplasia, type III"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • endocrine gland
    ³»ºÐºñ»ù, ³»ºÐºñ¼±
  • endocrine organ
    ³»ºÐºñ±â°ü
  • endocrine system
    ³»ºÐºñ°èÅë, ³»ºÐºñ°è
  • endocrine therapy
    ³»ºÐºñ¿ä¹ý
  • hereditary multiple exostosis
    À¯Àü´Ù¹ß»Àµ¹ÃâÁõ, À¯Àü´Ù¹ß¿Ü°ñÁõ
  • multiple
    ´Ù¹ß-, ¿©·¯-, ¹µ-, ´Ù¼ö-, ´ÙÁß-, ´Ù-
  • multiple abscess
    ¹µ°í¸§Áý, ´Ù¹ß³ó¾ç
  • multiple allele
    ¹µ¸Â¼¶À¯ÀüÀÚ, º¹¼ö´ë¸³À¯ÀüÀÚ
  • multiple birth
    ´Ùžƺи¸
  • multiple bond
    ´ÙÁß°áÇÕ
  • multiple character
    ´ÙÁß¼º°Ý
  • multiple correlation
    ´ÙÁß»ó°ü
  • multiple division
    º¹Çպп­
  • multiple drug resistance
    ´Ù¾àÁ¦³»¼º, ¿©·¯¾àÀúÇ×
  • multiple embolism
    ´Ù¹ß»öÀüÁõ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Borrmann type
    º¸¸£¸¸Çü
  • cellular type
    ¼¼Æ÷Çü
  • lepromatous type
    ³ªÁ¾Çü
  • scirrhous type
    °æÈ­Çü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • multiple birth
    ´Ù»ê, ´ÙÅÂÃâ»ê, °æ»ê
  • multiple bond
    ´ÙÁß°áÇÕ
  • multiple character
    ´ÙÁß¼º°Ý
  • multiple correlation
    ´ÙÁß»ó°ü
  • multiple deformity
    º¹ÇÕ±âÇü
  • multiple division
    º¹Çպп­
  • multiple dysplasia
    ¹µÇü¼ºÀå¾Ö
  • multiple personality disorder
    ´ÙÁßÀΰÝÀå¾Ö
  • hereditary multiple exostosis
    À¯Àü´Ù¹ß»Àµ¹ÃâÁõ
  • multiple embolism
    ´Ù¹ß»öÀüÁõ
  • multiple epitheliomatosis
    ´Ù¹ß»óÇÇÁ¾Áõ
  • multiple excitation
    ¹Ýº¹ÈïºÐ
  • multiple fetation
    ´Ù¼öÀÓ½Å
  • multiple fission
    ¹µºÐ¿­, ´Ù¼öºÐ¿­
  • multiple fracture
    ´Ù¹ß°ñÀý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • DSM-III
    Á¤½ÅÀå¾Ö(º´)Áø´ÜÅë°èÆí¶÷ Á¦ 3ÆÇ
  • DSM-III-R
    Á¤½ÅÀå¾Ö(º´)Áø´ÜÅë°èÆí¶÷ Á¦ 3ÆÇ °³Á¤ÆÇ
  • Sudan III
    ¼ö´Ü III
  • antithrombin III
    Çׯ®·Òºó III
  • apolipoprotein C-III
    ¾ÆÆ÷Áö´Ü¹é C-III
  • arsenazo III dye
    ¾Æ¸£¼¼³ªÁ¶<ºñ¼Ò¾ÆÁ¶> III ¿°·á
  • group III fiber
    Á¦¥²¤Çí·A.
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
  • platelet factor III
    Ç÷¼ÒÆÇÁ¦»ïÀÎÀÚ.
  • procollagen III peptide
    ÇÁ·ÎÄݶó°Õ III ÆéƼµå
  • pseudounipolar(bipolar III) disorder
    °¡¼º ´Ü±Ø¼º(¾ç±Ø¼º III)Àå¾Ö(º´).
  • B type virus particle
    BÇü ¹ÙÀÌ·¯½ºÀÔÀÚ.
  • B type virus particle
    BÇü ¹ÙÀÌ·¯½ºÀÔÀÚ.
  • C type particle
    CÇüÀÔÀÚ
  • C-type particle
    CÇü ÀÔÀÚ (·¹Æ®·Î¹ÙÀÌ·¯½ºÀÇ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • endometrial intraepithelial neoplasia
    Àڱ󻸷 »óÇdz»Á¾¾ç
  • gestational trophoblastic neoplasia
    Àӽżº À¶¸ð¼º Á¾¾ç
  • intraepithelial neoplasia
    »óÇdz» Á¾¾ç(¡­ ðþåË)
  • neoplasia
    ½Å»ý¹°
  • neoplasia
    ½Å»ý¹°
  • neoplasia
    Á¾¾ç (½Å»ý¹°)
  • prostatic intraepithelial neoplasia
    Àü¸³¼±»óÇdz»Á¾¾ç(îñí¡àÍß¾ù«Ò®ðþåË)
  • antithrombin III
    Çׯ®·Òºó III
  • apolipoprotein C-III
    ¾ÆÆ÷Áö´Ü¹é C-III
  • arsenazo III dye
    ¾Æ¸£¼¼³ªÁ¶<ºñ¼Ò¾ÆÁ¶> III ¿°·á
  • group III fiber
    Á¦¥²±º¼¶À¯(ÏØàéë«).
  • group III fiber
    Á¦¥²¤Çí·A.
  • oculomotor nerve (iii)
    ´«µ¹¸²½Å°æ
  • os metacarpale III ³ª
    ¼Â°¼Õ¹Ù´Ú<Áß¼ö>»À, Á¦»ïÁß¼ö°ñ(ð¯ß²ñéâ¢Íé).
  • platelet factor III
    Ç÷¼ÒÆÇÁ¦»ïÀÎÀÚ.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Muscular type of artery
    ±ÙÀ°Çüµ¿¸Æ
    [¿¾ ¿ë¾î] ±ÙÇüµ¿¸Æ
  • Muscular type of lymphatic vessel
    ±ÙÀ°Çü¸²ÇÁ°ü
    [¿¾ ¿ë¾î] ±ÙÇüÀӯİü
  • Muscular type of vein
    ±ÙÀ°ÇüÁ¤¸Æ
    [¿¾ ¿ë¾î] ±ÙÇüÁ¤¸Æ
  • Type B spermatogonium
    ´ÊÁ¤Á¶¼¼Æ÷
    [¿¾ ¿ë¾î] BÁ¤Á¶¼¼Æ÷
  • Anovulatory type
    ¹«¹è¶õÇü
    [¿¾ ¿ë¾î] ¹«¹è¶õÇü
  • Ovulatory type
    ¹è¶õÇü
    [¿¾ ¿ë¾î] ¹è¶õÇü
  • Irregular type
    ºÒ±ÔÄ¢Çü
    [¿¾ ¿ë¾î] ºÒ±ÔĢġ¹Ð°áÇÕÁ¶Á÷
  • Calcified hypertrophic type
    ¼®È¸È­ºñ´ëÇü
    [¿¾ ¿ë¾î] ¼®È¸È­ºñ´ëÇü
  • Fibrous type of lymphatic vessel
    ¼¶À¯Çü¸²ÇÁ°ü
    [¿¾ ¿ë¾î] ¼¶À¯ÇüÀӯİü
  • Type II hair cell
    ¿øÁÖÅм¼Æ÷
    [¿¾ ¿ë¾î] ÀüÆÄ¿¬Á¢¼¼Æ÷
  • Type A spermatogonium
    À¸¶äÁ¤Á¶¼¼Æ÷
    [¿¾ ¿ë¾î] AÁ¤Á¶¼¼Æ÷
  • Type I hair cell
    Á¶·Õ¹ÚÅм¼Æ÷
    [¿¾ ¿ë¾î] ¹è»ó¿¬Á¢¼¼Æ÷
  • Elastic type of artery
    ź·ÂÇüµ¿¸Æ
    [¿¾ ¿ë¾î] ź·ÂÇüµ¿¸Æ
  • Glomus type of arteriovenous anastomosis
    Å丮Çüµ¿Á¤¸Æ¿¬°á
    [¿¾ ¿ë¾î] ±¸Çüµ¿Á¤¸Æ¹®ÇÕ
  • Mixed type of artery
    È¥ÇÕÇüµ¿¸Æ
    [¿¾ ¿ë¾î] È¥ÇÕÇüµ¿¸Æ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ABO blood group (type) system
    ABOÇ÷¾×Çü (úìäûúþ) ½Ã½ºÅÛ
  • C-type particles
    C-Çü(û¡) ÀÔÀÚ(Ø£í­)
  • C-type virus
    "C-Çü(û¡) ¹ÙÀÌ·¯½º, (ÔÒ) C-type particles"
  • dehydrogenase-type mechanism
    µðÇÏÀ̵å·ÎÀú³×À̽ºÇü(úþ) ±âÀü(Ѧï®)
  • delayed-type hypersensitivity
    Áö¿¬Çü °ú¹ÎÁõ(òÀæÅû¡Î¦ÚÂñø)
  • immediate-type hypersensitivity
    Áï½ÃÇü °ú¹ÎÁõ(ñíãÁúþΦÚÂñø)
  • L-type structure
    L-Çü(úþ)±¸Á¶(ϰðã)
  • mixed-type inhibitor
    È¥ÇÕÇü ÀúÇØÁ¦(ûèùêúþîÁúªð¥)
  • plant-type ferredoxin
    ½Ä¹°Çü(ãÕÚªû¡) Æä·¹µ¶½Å
  • plaque-type mutant
    ÇöóÅ©Çü(û¡) º¯ÀÌü(ܨì¶ô÷)
  • transaminase-type mechanism
    Æ®¶õ½º¾Æ¹Ì³×À̽ºÇü (úþ) ±âÀü(Ѧï®)
  • type A hepatitis
    AÇü(úþ) °£¿°(ÊÜæú)
  • type A RNA virus
    AÇü(úþ) RNA ¹ÙÀÌ·¯½º
  • type B hepatitis
    BÇü(úþ) °£¿°(ÊÜæú)
  • type B RNA virus
    BÇü(úþ) RNA ¹ÙÀÌ·¯½º
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • multiple excitaiton
    ´ÙÁß¿©±â
  • multiple exostoses
    ´Ù¹ß¼º¿Ü°ñÁõ
  • multiple fibroma
    ´Ù¹ß¼º¼¶À¯Á¾
  • multiple lymphomatous polyposis
    ´Ù¹ß¼º¸²ÇÁÁ¾¼º¿ëÁ¾Áõ
  • multiple myeloma
    ´Ù¹ß¼º°ñ¼öÁ¾
  • multiple overlapping thin slab acquisition [=MOTSA]
    ´ÙÁßÁߺ¹¼¼ÆíÆÇȹµæ
  • multiple polyp
    ´Ù¹ß¼ºÆú¸³
  • multiple sclerosis
    ´Ù¹ß¼º°æÈ­Áõ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PMD Progressive Muscular Dystrophy; ÁøÇ༺ ±ÙÀÌ¿µ¾çÁõ
  Types of PMD(Progressive Muscular Dystroph...
FMEN familial multiple endocrine neoplasia
MEN multiple endocrine neoplasia
TAPVR Total Anomalous Pulmonary Venous Return
  = TAPVC
  4 Types of TAPVR
&...
CIN 3, CIN III cervical intraepithelial neoplasia, grade 3 (severe dysplasia and carcinoma in situ)
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MEN Multiple Endocrine Neoplasia
MEN I Multiple Endocrine Neoplasia
CIN III Cervical intraepithelial neoplasia grade III
GSD III Glycogen storage disease type III
HTLV III Human T Cell Lymphotropic Virus Type III
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lues III
    ¸Åµ¶ 3±â
    1. Èı⠸ŵ¶Àº ¸Å¿ì µå¹°´Ù. 2. ½É¸Æ°ü°è º´º¯ÀÌ 80¡­85%, ÁßÃ߽Űæ°è º´º¯ 5¡­10%, ³ª¸ÓÁö´Â °£À̳ª ´Ù¸¥ ºÎÀ§¿¡ °í¹«Á¾ÀÌ ¹ß»ýÇÑ´Ù.
  • platelet fector III
    Ç÷¼ÒÆÇ Á¦ »ï ÀÎÀÚ
  • pseudo class III
    °¡¼º III ±Þ
  • pseudotumour :

    pseudounipolar bipolar III disorder

    °¡¼º ´Ü±Ø¼º ¾ç±Ø¼º III Àå¾Ö, °¡¼º ´Ü±Ø¼º ¾ç±Ø¼º III º´
  • transverse facial fracture : µ¿ÀǾî=Le Forte III fracture.

    transverse facial vein

    °¡·Î ¾ó±¼ µ¿¸Æ
  • true class III
    Áø¼º III±Þ ºÎÁ¤ ±³ÇÕ
  • affecting multiple system
    ´Ù¹ß¼º °èÅëÀ» ħ¹üÇÑ
  • multiple
    ´Ù¹ß¼º, ´Ù¼öÀÇ
  • multiple abutment
    ´Ù¼ö Áö´ëÄ¡
  • multiple allelomorph
    º¹´ë¸³ À¯ÀüÀÚ
  • multiple anchorage
    º¹ÇÕ °íÁ¤
    1Çü½Ä ÀÌ»óÀÇ ÈûÀ» °¡ÇÏ´Â ÀåÄ¡¸¦ »ç¿ëÇÏ´Â °íÁ¤.
  • multiple angioma
    ´Ù¹ß¼º ¸Æ°üÁ¾
  • multiple biologically active peptide fragment
    ´Ù¹ß¼º »ý¹°ÇÐÀû Ȱ¼º ÆéŸÀÌµå ºÐÀý
  • multiple cavernous hemangioma
    ´Ù¹ß¼º ÇØ¸é Ç÷°üÁ¾
  • multiple condylome
    ´Ù¹ß¼º ½À¿ì
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
hyperlipoproteinaemia type III A rather uncommon form of familial hyperlipaemia characterised by the presence of lipoproteins of abnormal composition. The main abnormal lipoproteins are called beta-vldl and have a different apoprotein content and a higher proportion of cholesterol relative to triglyceride than normal vldl.
(12 Dec 1998)
deoxyribonucleases, type III site-specific <enzyme> Enzyme systems composed of two subunits and requiring ATP and magnesium for endonucleolytic activity; they do not function as atpases. They exist as complexes with modification methylases of similar specificity.
The systems recognise specific short DNA sequences and cleave a short distance, about 24 to 27 bases, away from the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.5
(12 Dec 1998)
type III acrocephalosyndactyly An autosomal dominant syndrome with variable expression of brachycephaly, maxillary hypoplasia, prominent ear crus, syndactyly, facial asymmetry, shallow orbits, telecanthus, and nasal septal deviation; may show mental retardation.
Synonym: Saethre-Chotzen syndrome.
(05 Mar 2000)
type III collagen Collagen characteristic of reticular fibres.
(05 Mar 2000)
type III familial hyperlipoproteinaemia Hyperlipoproteinaemia characterised by increased plasma levels of LDL, beta-lipoproteins, pre-beta-lipoproteins, cholesterol, phospholipids, and triglycerides; hypertriglyceridemia induced by a high carbohydrate diet, and glucose tolerance is abnormal; frequent eruptive xanthomas and atheromatosis, particularly coronary artery disease; biochemical defect lies in apolipoproteins; there are many varieties.
Synonym: carbohydrate-induced hyperlipaemia, dysbetalipoproteinaemia, familial hyperbetalipoproteinaemia and hyperprebetalipoproteinaemia, familial hypercholesterolaemia with hyperlipaemia.
(05 Mar 2000)
type III hyperlipoproteinaemia <biochemistry> An inherited disorder (gene defect) where both cholesterol and triglycerides are elevated in the same patient. This condition accelerates the effects of atherosclerosis and thus increases the risk of cardiovascular disease. Conditions such as hypothyroidism, obesity and diabetes enhances this risk.
Origin: Gr. Haima = blood
(27 Sep 1997)
type III hypersensitivity reaction An immunologic category of diseases evoked by the deposition of antigen-antibody or antigen-antibody-complement complexes on cell surfaces, with subsequent involvement of breakdown products of complement, platelets, and polymorphonuclear leukocytes, and development of vasculitis; nephritis is common. Arthus phenomenon and serum sickness are classic examples, but many other disorders, including most of the connective tissue disease's, may belong in this immunologic category; immune complex disease's can also occur during a variety of disease's of known aetiology, such as subacute bacterial endocarditis.
See: autoimmune disease.
Synonym: immune complex disorder, type III hypersensitivity reaction.
(05 Mar 2000)
type III mucopolysaccharidosis <syndrome> An error of the mucopolysaccharide metabolism, with excretion of large amounts of heparan sulfate in the urine and severe mental retardation with hepatomegaly; skeleton may be normal or may present mild changes similar to those in Hurler's syndrome; several different types (A, B, C, and D) have been identified according to the enzyme deficiency; autosomal recessive inheritance.
Synonym: type III mucopolysaccharidosis.
(05 Mar 2000)
multiple lipoprotein-type hyperlipidaemia <biochemistry> Inherited as a defective gene, this disorder is characterised by elevations in serum cholesterol and/or triglycerides. There are often multiple types of lipoproteins (LDL) elevated in one family. This condition is associated with an increased risk of cardiovascular disease.
Origin: Gr. Haima = blood
(27 Sep 1997)
cervical intraepithelial neoplasia A term which describes precancerous changes to the epithelial cells lining the cervix. The diagnosis is made from the microscopic examination of a PAP smear acquired tissue specimen. Less than 5% of all PAP smears will show cervical dysplasia. The peak incidence is in women 25 to 35 years of age. Risk factors include multiple sexual partners, early onset of sexual activity (less than 18), early childbearing (less than 16) and past medical history of a sexually transmitted disease (for example genital warts, genital herpes, HIV infection). Treatment is based on the degree of dysplasia present, as judged by a pathologist. Treatments include cryotherapy and conisation.
Origin: Gr. Plassein = to form
(27 Sep 1997)
prostatic intraepithelial neoplasia A premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. The neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer.
(12 Dec 1998)
neoplasia <oncology, pathology> Literally new growth, usually refers to abnormal new growth and thus means the same as tumour, which may be benign or malignant.
Unlike hyperplasia, neoplastic proliferation persists even in the absence of the original stimulus.
Origin: Gr. Plassein = to form
(18 Nov 1997)
lobular neoplasia <tumour> Carcinoma of the breast in which small tumour cells fill preexisting acini within lobules, without invading the surrounding stroma.
Synonym: lobular carcinoma in situ, lobular neoplasia.
(05 Mar 2000)
bone diseases, endocrine Diseases of the bones related to hyperfunction or hypofunction of the endocrine glands.
(12 Dec 1998)
neoplastic endocrine-like syndromes Endocrine syndromes due to hormone production by neoplasms of non-endocrine tissue, or by other than the usual endocrine tissues. They are often the first indication of a previously undetected neoplasm.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cold type
    ÄݵåŸÀÌÇÁ(»çÁø.½ÄÀÚµî ȰÀÚ ÁÖÁ¶¸¦ ÇÏÁö ¾Ê´Â ½ÄÀÚ)
  • cold type system
    Äݵå ŸÀÌÇÁ ½Ã½ºÅÛ(³³È°ÀÚ³ª ¿­À» »ç¿ëÇÏÁö ¾Ê°í Çʸ§À» ÁÖü·ÎÇÑ »ç½ÄÈ­¿¡ ÀÇÇÑ Àμ⠰øÁ¤
  • condensed type
    °¡´Ã°í ±ä ȰÀÚ
  • display type
    Ç¥Á¦;±¤°í¿ëÀÇ ´ëÇü ȰÀÚ
  • foundry type
    ¼öÁ¶ÆÇ ȰÀÚ
  • ideal type
    ÀÌ»óÇü
  • italic type
    (ÀÎ)ÀÌÅÚ¸¯Ã¼;»çü
  • moon type
    (¸ÍÀοëÀÇ)¹®½Ä¼±ÀÚ
  • repulsive(-type) maglev
    ¹Ý¹ß½Ä Àڱ⠺λó(Â÷ü¸¦ ¶ß°ÔÇϱâ À§ÇØ ÀüÀÚ¼®ÀÇ ¹Ý¹ß·ÂÀ» ÀÌ¿ë)
  • type
    Çü;À¯Çü;¾ç½Ä;ÀüÇü;°ßº»;Ç¥;ȰÀÚ;Ç÷¾×Çü;in ~ ȰÀڷΠ§(Â¥¼­);set ~ Á¶ÆÇÇÏ´Ù
  • type
    ŸÀÌÇÁ¶óÀÌÅÍ·Î Âï´Ù;(Ç÷¾×)ÇüÀ» °Ë»çÇÏ´Ù;»ó¡ÇÏ´Ù;...ÀÇ ÀüÇüÀÌ µÇ´Ù
  • type cast
    (±ØÁß Àι°ÀÇ ½ÅÀå,¸ñ¼Ò¸® µûÀ§¿¡ ¸Â´Â) ¹è¿ì¸¦ ¹è¿ªÇÏ´Ù
  • type founder
    ȰÀÚ ÁÖÁ¶°ø(¾÷ÀÚ)
  • type metal
    ȰÀÚ ÇÕ±Ý
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á